Raymond James Financial Inc. bought a new position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,112,275 shares of the biotechnology company's stock, valued at approximately $19,076,000. Raymond James Financial Inc. owned about 0.47% of ADMA Biologics as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently made changes to their positions in the stock. First Business Financial Services Inc. bought a new position in ADMA Biologics during the fourth quarter valued at approximately $343,000. Vision Financial Markets LLC bought a new position in ADMA Biologics during the fourth quarter valued at approximately $51,000. Arizona State Retirement System lifted its position in ADMA Biologics by 6.6% during the fourth quarter. Arizona State Retirement System now owns 67,581 shares of the biotechnology company's stock valued at $1,159,000 after purchasing an additional 4,170 shares during the period. Victory Capital Management Inc. lifted its position in ADMA Biologics by 52.8% during the fourth quarter. Victory Capital Management Inc. now owns 109,948 shares of the biotechnology company's stock valued at $1,886,000 after purchasing an additional 38,002 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in ADMA Biologics by 1.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,440,294 shares of the biotechnology company's stock valued at $41,851,000 after purchasing an additional 38,761 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.
ADMA Biologics Stock Performance
ADMA traded down $0.98 during trading on Thursday, hitting $19.63. The company's stock had a trading volume of 4,223,928 shares, compared to its average volume of 3,339,695. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a one year low of $5.90 and a one year high of $23.64. The firm has a market cap of $4.64 billion, a PE ratio of 70.11 and a beta of 0.60. The business's 50 day simple moving average is $16.71 and its 200-day simple moving average is $18.00.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.
Get Our Latest Stock Report on ADMA Biologics
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Articles
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
